Stay updated on Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial

Sign up to get notified when there's something new on the Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for the completed NCT02252172 multiple-myeloma trial, including its treatments, eligibility criteria, outcomes, and study publications, instead of a 403 error.
    Difference
    100%
    Check dated 2026-11-11T17:40:08.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.2 to v3.8.0; the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-28T15:51:28.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A sitewide banner announces NIH website transition updates and says that federal agencies are using “Super Intelligence” instead of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-21T20:21:07.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2; the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-14T19:57:10.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer revision label was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-07T20:27:29.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Access to the study page is blocked by a 403 Forbidden error, replacing the detailed study content with an error screen. The previously visible documents and sections are removed, leaving only the header and footer.
    Difference
    15%
    Check dated 2026-09-23T21:35:10.000Z thumbnail image

Stay in the know with updates to Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial page.